- ASSISTANT PROFESSOR Developmental and Regenerative Biology
National Diploma, University of Bucharest
Physics and Biophysics
Ph.D., Institute of Cellular Biology and Pathology
Cell and Molecular Biology
I am doing research on a new marker of tumor blood vessels that we recently discovered in collaboration with the lab of Dr. Nicolae Ghinea from INSERM France. The marker is present in all major eleven tumor types that we investigated.
We are testing in mice the possibility of using this marker for tumor imaging and for targeting therapeutic agents. In parallel we are working towards elucidating the mechanism that leads to the expression of the marker in tumors and to clarify if the marker contributes to tumor growth.
Another area of investigation consists in perturbed intracellular traffic processes in the neurons of Alzheimer disease patients, which contribute to tau hyperphosphorylation and formation of neurofibrillary tangles.
I am also doing research on aging at cellular and molecular levels in mammalian organisms using bionformatics methods.
Radu A, Hristescu G, Katsel P, Haroutunian V, Davis KL. Microarray database mining and cell differentiation defects in schizophrenia. Adv Exp Med Biol 2010;.
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Vu Hai M, Ghinea N. Blood vessel endothelium expresses FSHR in a wide range of human cancers . New Engl J Med 2010 Oct; 363(17): 1621-1630.
Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K. The Carboxy Terminal Fragment of Inhibitor-2 of Protein Phosphatase-2A Induces Alzheimer Disease Pathology and Cognitive Impairment [epub ahead of print]. FASEB J 2010 July;.
Vu Hai M, Radu A, Ghinea N. The cleavage of thyroid stimulating hormone receptor is dependent on cell-cell contacts and regulates the hormonal stimulation of phospholipase C. J. Cell. Mol. Med. 2009; 3(8B): 2253-60.
Ploski JE, Topisirovic I, Park KW, Borden KL, Radu A. A mechanism of nucleocytoplasmic trafficking for the homeodomain protein PRH. Mol Cell Biochem 2009; 332(1-2): 173-81.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Radu did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 25 Room 10 B
1468 Madison Avenue
New York, NY 10029